title: Banking of pluripotent adult stem cells as an unlimited source for red blood cell production: potential applications for alloimmunized patients and rare blood challenges.
abstract: The transfusion of red blood cells (RBCs) is now considered a well-settled and essential therapy. However, some difficulties and constraints still occur, such as long-term blood product shortage, blood donor population aging, known and yet unknown transfusion-transmitted infectious agents, growing cost of the transfusion supply chain management, and the inescapable blood group polymorphism barrier. Red blood cells can be now cultured in vitro from human hematopoietic, human embryonic, or human-induced pluripotent stem cells (hiPSCs). The highly promising hiPSC technology represents a potentially unlimited source of RBCs and opens the door to the revolutionary development of a new generation of allogeneic transfusion products. Assuming that in vitro large-scale cultured RBC production efficiently operates in the near future, we draw here some futuristic but realistic scenarios regarding potential applications for alloimmunized patients and those with a rare blood group. We retrospectively studied a cohort of 16,486 consecutive alloimmunized patients (10-year period), showing 1 to 7 alloantibodies with 361 different antibody combinations. We showed that only 3 hiPSC clones would be sufficient to match more than 99% of the 16,486 patients in need of RBC transfusions. The study of the French National Registry of People with a Rare Blood Phenotype/Genotype (10-year period) shows that 15 hiPSC clones would cover 100% of the needs in patients of white ancestry. In addition, one single hiPSC clone would meet 73% of the needs in alloimmunized patients with sickle cell disease for whom rare cryopreserved RBC units were required. As a result, we consider that a very limited number of RBC clones would be able to not only provide for the need for most alloimmunized patients and those with a rare blood group but also efficiently allow for a policy for alloimmunization prevention in multiply transfused patients.
authors.affiliation: Institut National de la Transfusion Sanguine, Paris, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Peyrard
authors.forename: Laurent
authors.initials: L
authors.lastname: Bardiaux
authors.forename: Claire
authors.initials: C
authors.lastname: Krause
authors.forename: Ladan
authors.initials: L
authors.lastname: Kobari
authors.forename: Hélène
authors.initials: H
authors.lastname: Lapillonne
authors.forename: Georges
authors.initials: G
authors.lastname: Andreu
authors.forename: Luc
authors.initials: L
authors.lastname: Douay
mesh_terms: D000328:Adult; D053687:Adult Stem Cells; D000818:Animals; D000094902:Blood Banking / Q000379:methods*; D001788:Blood Grouping and Crossmatching / Q000379:methods*; D001800:Blood Specimen Collection / Q000379:methods; D002454:Cell Differentiation; D017707:Erythrocyte Transfusion / Q000379:methods; D004912:Erythrocytes / Q000502:physiology*; D006801:Humans; D007518:Isoantibodies / Q000009:adverse effects / Q000276:immunology*; D039904:Pluripotent Stem Cells
chemical_list: D007518:Isoantibodies